News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Chinmay Jani: EGFR mutation and treatment selection post-osimertinib progression at WLC25
Chinmay Jani/X
Feb 4, 2025, 16:52

Chinmay Jani: EGFR mutation and treatment selection post-osimertinib progression at WLC25

Chinmay Jani, Clinical Fellow of Hematology and Oncology at the University of Miami, shared a post on X:

“Had a great experience presenting at PER our case on EGFR mutation and treatment selection post-osimertinib progression. What would be your go-to approach?

Huge thanks to Estela Rodriguez, Gilberto Lopes, Julie Brahmerand Julie Brahmer for the opportunity!”

Chinmay Jani: EGFR mutation and treatment selection post-osimertinib progression at WLC25

More posts featuring Chinmay Jani.

cancer Chinmay Jani OncoDaily Oncology
Special Coverage
Blog
Feb 4, 2025, 16:52
Chinmay Jani: EGFR mutation and treatment selection post-osimertinib progression at WLC25
Science
Feb 4, 2025, 16:52
DDR mutations and outcome in biliary tract cancers
Science
Feb 4, 2025, 16:48
Durable responses in SCLC with Tarlatamab by Jacob Sands et al. - ACS Journal Cancer
Science
Feb 4, 2025, 16:37
Eirini Papapetrou: Our new review article on leukemia stem cells
Blog
Feb 4, 2025, 16:31
Estela Rodriguez: Discussing emerging therapies in lung cancer at WLC25
Blog
Feb 4, 2025, 16:27
Shaibu Issa: Working everyday to make healthier communities
Blog
Feb 4, 2025, 16:23
Guru Sonpavde: Current therapy and recent advances in bladder cancer treatment at APPOS25
Blog
Feb 4, 2025, 16:19
Supporting AANHPI communities - LUNGevity Foundation
Science
Feb 4, 2025, 16:13
Kristina Jankovic: Bone health in newly diagnosed female breast cancer patients in China
Career
Feb 4, 2025, 16:11
Jos Jonkers - Candidate for the Nominating Committee of AACR
Science
Feb 4, 2025, 16:09
Hidehito Horinouchi: Enhancing performance of automatic trial matching tools in molecular tumor boards
Career
Feb 4, 2025, 16:01
ESO Further Educational Grant Recipients for 2025